Study identifier:D7830C00001
ClinicalTrials.gov identifier:NCT04142424
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2693 Following Single Ascending Dose Administration in Male and Female Subjects of Non-childbearing Potential in Overweight but Otherwise Healthy Subjects, and Healthy Chinese and Japanese Subjects
Metabolic disorders
Phase 1
Yes
AZD2693, Placebo
All
73
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Nov 2021 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1 healthy subjects: AZD2693 Dose 1 Subjects will receive a subcutaneous (SC) injection of single dose 1 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 2 healthy subjects: AZD2693 Dose 2 Subjects will receive a SC injection of single dose 2 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 3 healthy subjects: AZD2693 Dose 3 Subjects will receive a SC injection of single dose 3 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 4 healthy subjects: AZD2693 Dose 4 Subjects will receive a SC injection of single dose 4 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 5 healthy subjects: AZD2693 Dose 5 Subjects will receive a SC injection of single dose 5 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 6 healthy subjects: AZD2693 Dose 6 Subjects will receive a SC injection of single dose 6 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 7 healthy Japanese subjects: AZD2693 Dose 7 Subjects will receive a SC injection of single dose 7 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 8 healthy Japanese subjects: AZD2693 Dose 8 Subjects will receive a SC injection of single dose 8 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |
Experimental: Cohort 9 healthy Chinese subjects: AZD2693 Dose 9 Subjects will receive a SC injection of single dose 9 of AZD2693 or placebo matched to AZD2693 on Day 1. | Drug: AZD2693 Subjects will receive SC injection of AZD2693 as per the arms they are randomized. Drug: Placebo Subjects will receive SC injection of placebo matched to AZD2693, as per the arms they are randomized. |